Gabriel Roberti, MD

Pathologist interested in Urologic and Molecular Pathology | Postdoc Research Fellow @BrighamWomens and @HarvardMed

[Renee Maria Saliby @ReneeSaliby]

EV/P delivers again!!

Congrats to @MattGalsky , investigators and patients on EV/P showing prolonged EFS and OS compared to neoadjuvant gem/cis

A pivotal moment indeed #GU26

@OncoAlert

[Marc Machaalani, MD @MarcMachaalani]

Kidney day at #GU26 with many exciting posters from friends and colleagues:

[Gabriel Roberti, MD @Gabriel_Pathol]

@MarcMachaalani @ASCO @OncoAlert @DanaFarber_GU @eddy_saad @Chrislabaki1 @ZiadBakouny @BradMcG04 @IMG_Oncologists @OncoBellmunt @DrChoueiri Congratulations 👏🏽

[David Einstein @davidjeinstein]

How to ever do sequencing studies with so many options coming down the pike? @Uromigos

[Sounak Gupta @Shounak_Gupta]

An open access guide to renal medullary carcinoma:

https://t.co/VbOLkYMt11

[Carlos Alvarez @duemed]

My table on histologic subtypes of urinary tract tumors during #simposioSOGUG25 @sogug1

🔸 UC with mixed HS has different biological behaviors.

🔸 Mixed variants are managed (so far) as conventional UC with the exception of small cell. #bladdercancer

[Michelle_Hirsch (Donovan) @MichelleDunno17]

Eosinophilic Vacuolated Tumor (EVT) - generally considered benign/indolent & associated with MTOR pathway mutations. However, rarely it can be seen w/metastatic dz, as seen here (LVI+, LN+). 🔬@GU_Path_Society @IntSocUropath @AdanmaAnjiMD @Kiril_T_Can

https://t.co/kVO6K2Bccu

[Dana-Farber News @DanaFarberNews]

Some prostate cancers evade therapy by transforming into aggressive neuroendocrine prostate cancer. New research highlights PROX1 as a key driver of this transformation and tumor growth, offering a potential treatment target.

➡️ https://t.co/KUL6C6c9LE

@CR_AACR @bajji @mishabeltran

[Ting Zhao, MD @TingZhaoPathdoc]

60s M with a renal mass. What is your diagnosis?
#PathTwitter
@MGBpathology @MGHPathology

[Yakup Ergün @dr_yakupergun]

Ovarian Cancer

https://t.co/mr6eJgpg3q

[Gabriel Roberti, MD @Gabriel_Pathol]

So proud to be part of this incredible research team! #KCRS25 #pathology #kidneycancer @kidneycan

[ROHIT MEHRA @drmehrarohit]

Insightful discussions, cutting edge research, great speakers, multidisciplinary approach & an amazing audience- perfect #kidneycancer meeting @kidneycan #KCRS2025 #genomics #pathology #cancer

[Yüksel Ürün @DrYukselUrun]

Molecular and Therapeutic Landscape of Non-Clear Cell Renal Cell Carcinoma:
🧬🧬🧬Diverse subtypes, unique genetics, unpredictable responses.
@NatRevUrol @OncoAlert @kidneycan @IKCCorg @KidneyCancer @MehrazinMD
https://t.co/MLTO3sTjkb

[Michelle_Hirsch (Donovan) @MichelleDunno17]

Enjoy Kidney Cancer's Special Pathology Edition. A great set of [open access] RCC reviews; also, sarcomas, benign tumors, molecular changes, familial syndromes, grading/staging. Great for patients, clinicians, researchers & pathologists.🔬#gupath @urotoday
https://t.co/SqPrtyY2Z1

[Eric Green @NHGRI_Director]

This helpful infographic from @genome_gov explains the challenges of sequencing highly repetitive DNA and the technological advances that were needed to generate the first truly complete (gapless) human genome sequence. I encourage you to check it out! https://t.co/k732fM97td

[Histopathology @Histo_Journal]

Assessment and classification of sex cord‐stromal tumours of the testis: recommendations from the testicular sex cord‐stromal tumour (TESST) group, an Expert Panel of GUPS and ISUP- Acosta - Histopathology - Wiley Online Library #openaccess https://t.co/aFrOkVDYKN

[European Association of Urology (EAU) @Uroweb]

🧾 Cheat Sheet on Follow-up for NMIBC

🔹 Risk-based surveillance
🔹 Lifelong follow-up for high-risk patients
🔹 Role of cytology & markers
🔍 No substitute for cystoscopy

Download Cheat Sheet:
https://t.co/M7etsv1fhi

#BladderCancer #NMIBC #EAUguidelines

[Gladell Paner, MD @GladellPaner]

Unique pattern of an uncommon #testis tumor.

What’s is your diagnosis #GUPath tweeps? #OnePicDx

Answer in comment👇👇👇

[Mass General Brigham Pathology @MGBpathology]

Big news!
Massachusetts General Hospital and Brigham and Women’s Hospital have been ranked #1 and #2 globally for research impact among healthcare institutions by the 2024 @NatureIndex.
Proud to be part of a pathology department at the forefront of discovery! 🧪🔬
#PathTwitter